Endeavor

28 WAVETEC TOBIAS BESSONE UAE - Enterprise Software & Services Z I PPE D I LUIS VERA Chile - Enterprise Software & Services Hate waiting in lines? As stores and branches work to optimize and transform their on-site experience, the global customer experience management (CEM) industry is growing at a 19.9% CAGR toward an expected $10.8B by 2020 (MarketsandMarkets). With a suite of queue management technologies and self service kiosks, Wavetec decreases wait times and improves customer satisfaction at stores, banks, telcos and government institutions in 75 countries. Also a leading provider of financial LED displays, Wavetec has installed large data displays in 25 stock exchanges and financial houses around the world. Over the last five years, sales of Wavetec's CEM solutions have tripled. Moving forward, Wavetec aims to achieve US$100M in turnover by 2022 by concentrating global sales efforts on its CEM suite. Zippedi is a B2B retail tech company that uses artificial intelligence, deep learning, and robotics to capture, digitize, process, and analyze on-shelf information from brick and mortar retailers with the objective of providing retail industry players with timely, previously unavailable information from their physical stores. The information is provided in a cost-effective, convenient, and actionable manner that helps retail industry players (e.g. supermarkets, home improvement stores, suppliers, and retail industry service providers) improve their overall operations. U N I M A I N C . JOSE LUIS NUÑO AYALA Mexico - Healthcare A clean bill of health shouldn't cost an arm and a leg. For the rural poor in developing countries, doctors are hard to come by, and diagnosing diseases requires sending away tests to lab facilities — a costly and time-intensive ordeal. Unima is lowering the cost and time to access medical support with Signatural, a diagnostic technology that costs consumers US$1 and takes less than 15 minutes to diagnose a disease. As the first Mexican company to participate in Y Combinator, Unima has developed tests for HIV, TB, and influenza, and is currently starting clinical trials to commercialize its first products in late 2017. With over three billion people in developing countries living without access to timely diagnostics, Unima is poised to tackle the US$15 billion point-of-care diagnostics market and help those at the bottom of the pyramid battle infectious diseases.

• Cover